The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

lineagen.com

Founded Year

2002

Stage

Acquired | Acquired

Total Raised

$60.37M

Valuation

$0000 

About LineaGen Research

Lineagen's mission is to accelerate and enhance the diagnostic evaluation of medical conditions so that the best possible outcomes can be achieved for patients and their families. The company's first commercial offering, FirstStepDx PLUS, provides physicians with a fully integrated genetic testing, counseling, and developmental screening service to aid in the diagnostic evaluation of individuals with ASD or other forms of developmental delay. In addition to its deep commitment to ASD and developmental delay, the company has ongoing scientific programs in the areas of multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD).On August 24th, 2020, LineaGen Research was acquired by Bionano Genomics at a valuation of $9.6M.

LineaGen Research Headquarter Location

2677 E Parleys Way

Salt Lake City, Utah, 84109,

United States

801-931-6200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing LineaGen Research

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LineaGen Research is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

LineaGen Research Patents

LineaGen Research has filed 21 patents.

The 3 most popular patent topics include:

  • Genetics
  • Autism
  • Psychiatric diagnosis
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/3/2012

4/17/2018

Respiratory therapy, Lung disorders, Muscarinic antagonists, Respiratory diseases, Respiratory physiology

Grant

Application Date

7/3/2012

Grant Date

4/17/2018

Title

Related Topics

Respiratory therapy, Lung disorders, Muscarinic antagonists, Respiratory diseases, Respiratory physiology

Status

Grant

Latest LineaGen Research News

BNGO Stock Price Increases 1,552.94% Over The Past Month: Why It Happened

Jan 17, 2021

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 1,552.94% over the past month. This is why it happened. Bionano is a genome analysis company that provides tools and services based on the Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. And the Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes — which is known as cytogenetics. The Saphyr system is built with an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services for providing access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. And Lineagen has been providing genetic testing services to families and their healthcare providers for over 9 years and has performed over 65,000 tests for those with neurodevelopmental concerns. The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 1,552.94% over the past month as it went from $0.51 on December 16 to $8.43 on January 15. There were several triggers that sent the stock price up. Late December In late December, Oppenheimer analyst Kevin DeGeeter maintained a “Buy” rating on BNGO. And DeGeeter set a price target of $1.50 on the company. And Maxim Group analyst Jason McCarthy assigned a “Buy” rating shortly after at a price target of $2. At the time, the stock price was trading somewhere between $0.55 and $0.88. The analysts had cited Bionano Genomics’ key milestones for throughput of the Saphyr System. And with the release of a software update for the Saphyr Instrument — which is part of its system for optical genome mapping, the system became capable of imaging up to 96 human genomes per week to a depth of coverage of 100x (or 4,992 samples per year) assuming continuous operation. Since Saphyr launched in 2017, the annual throughput has increased 1,400%, from 384 samples per year to nearly 5,000 samples per year. And the expansion in throughput has been driven largely by the growing use of the Saphyr System in a variety of high volume settings, including discovery research and cytogenomics. The software update also included Saphyr Assure, which offers an automated system health monitoring tool that continuously inspects data quality and instrument performance. Saphyr Assure was built to monitor Saphyr’s health and can alert Bionano support of potential issues. January 4 – Study Published About Autism Risk Genes Between December 31 and January 4, the stock price of BioNano went from $3.08 to $7.20 (up 133.77%). One of the biggest reason why the stock price increased at that time is due to the company announcing that it published a study on autism risk genes after detailed analysis of the genome of Professor Temple Grandin — who brought awareness to auAutism Spectrum Disorder (ASD) through her activism. Through the use of the Lineagen’s suite of genetic tests customized for individuals with ASD and other disorders of childhood development, including FirstStepDx PLUS chromosomal microarray, NextStepDx PLUS whole exome sequencing, and whole genome sequencing, the study had identified novel variants in known ASD risk genes and other genetic variants important to her health and wellness. And despite Dr. Grandin’s high level of functioning and acute awareness of how her ASD manifests, the findings have led to improved clinical management of many of her symptoms. Dr. Grandin was diagnosed with ASD during childhood and was non-verbal until age 3. And she avoided physical touch and had difficulties with social interactions as an adolescent yet she was able to develop a career as a renowned PhD scientist, authored books entitled “The Autistic Brain” and “Thinking in Pictures” and was named one of the top 10 college professors by CEOWORLD Magazine. Along with having ASD, she has experienced a lifelong feeling of heat and pain (specifically in her feet), insomnia, anxiety and panic attacks and is missing several teeth but elected to forego dental implants. Lineagen’s genome analysis had identified sequence variants in three ASD risk genes — one of which was initially discovered and validated by Lineagen, and structural variants in other neurodevelopmental genes that — while not considered diagnostic on their own — in combination could explain her ASD and related health conditions. Plus, pathogenic variants were found in genes that explain her symptoms of pain (familial Mediterranean fever) and missing teeth (ectodermal dysplasia). And her decision to forego dental implants ended up being the right one given the bone weakness caused by ectodermal dysplasia. And analysis of pharmacogenetic genes found her to have a slow metabolism of many drugs, including Warfarin — which meant that her prescriptions and dosage had to be adjusted. Without such critical information, there could have been significant bleeding-related issues during surgery. “This publication shows the importance of genetic testing for ASD and neurodevelopmental disorders. ASD is typically diagnosed based on a child’s behavior, and only 3% of children with an ASD diagnosis get clinical genetic testing, which is recommended by a number of professional medical organizations including the American College of Medical Genetics and Genomics and the American Academy of Pediatrics. Widespread adoption of genetic testing is important to patients and families because it creates a better understanding of ASD, but more importantly, informs families and patients about immediate health risks associated with ASD that could personalize treatment options and provide potentially life-saving information,” said Erik Holmlin, PhD, CEO of Bionano Genomics. January 11 On January 11, Bionano Genomics, Inc. announced the first publication from the COVID-19 Host Genome Structural Variant Consortium. And the study found that optical genome mapping (OGM) with Bionano’s Saphyr System identified structural variants (SVs) that affect genes in pathways that control immune and inflammatory response, viral reproduction, and mucosal function. The authors believed these SVs may provide key insights into the pathogenesis of COVID-19 and outcomes in patients who become severely ill. The stock price increased over 20% when this was announced. January 13 On January 13, Bionano Genomics announced that it received a letter from the Nasdaq Listing Qualifications staff notifying the company has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The letter had noted that as for the last 10 consecutive business days, from December 29, 2020, to January 12, 2021, the closing bid price of the company’s common stock has been at $1 per share or greater, the company has regained compliance and the matter is now closed. The stock price increased over 49% when this was announced. Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

  • When was LineaGen Research founded?

    LineaGen Research was founded in 2002.

  • Where is LineaGen Research's headquarters?

    LineaGen Research's headquarters is located at 2677 E Parleys Way, Salt Lake City.

  • What is LineaGen Research's latest funding round?

    LineaGen Research's latest funding round is Acquired.

  • How much did LineaGen Research raise?

    LineaGen Research raised a total of $60.37M.

  • Who are the investors of LineaGen Research?

    Investors of LineaGen Research include BioNano Genomics, Sanderling Ventures, PrairieGold Venture Partners, Mesa Verde Venture Partners, Signal Peak Ventures and 14 more.

  • Who are LineaGen Research's competitors?

    Competitors of LineaGen Research include Brain Tunnelgenix Technologies, STARR Life Sciences, Integrated Diagnostics, Advanced Cell Diagnostics, Magellan Biosciences and 9 more.

You May Also Like

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

G
Glycominds

Glycominds Ltd. holds knowledge and experience in the field of glycomics, utilized for the discovery and development of glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.

h
hanse chemie GmbH

Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.

N
NeoDiagnostix

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

N
Novx

NOVX Systems is a medical device company that is combing expertise in photonics, engineering, polymer chemistry, physics, molecular biology and data management, to create solutions for office-based patient testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.